SCHEMBL23040976

SCHEMBL23040976

COC(=O)c1ccc(CCc2cccc(Cl)c2)c(C(=O)OC)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 2/20 0.51
CYP4A11 Q02928 2/20 0.51
ACHE P22303 1/20 0.48
HSP90AA1 P07900 1/20 0.47
LOXL2 Q9Y4K0 1/20 0.46
TRPV1 Q8NER1 1/20 0.45
PLA2G2A P14555 1/20 0.45
PTGER4 P35408 1/20 0.44
MAOB P27338 2/20 0.43
ALDH1A1 P00352 1/20 0.43
TP53 P04637 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
HPGD P15428 1/20 0.43
ALOX15 P16050 1/20 0.43
ALOX12 P18054 1/20 0.43
CYP2C19 P33261 1/20 0.43
CKS1B P61024 1/20 0.43
SKP2 Q13309 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30692045 1.00 CYP4F2 (0.51) CYP4F2CYP4A11ACHEHSP90AA1LOXL2
SCHEMBL17978223 0.85 ABCB1 (0.54) CYP4F2CYP4A11HDAC1NPC1RAB9A
SCHEMBL5365504 0.79 HSP90AA1 (0.53) HSP90AA1PLA2G2APTGER4MAOBALDH1A1
SCHEMBL23040963 0.79 RXRA (0.51) ALDH1A1HPGDMRGPRX4HDAC1TAAR1
SCHEMBL30186713 0.79 RXRA (0.52) MAOBCYP1A2CYP2C9CYP2C19HIF1A
SCHEMBL24926716 0.79 RXRA (0.52) MAOBCYP1A2CYP2C9CYP2C19HIF1A
SCHEMBL7241172 0.77 CCR6 (0.53) CYP4F2CYP4A11LOXL2PLA2G2AALDH1A1
SCHEMBL70173 0.75 CYP4F2 (0.83) CYP4F2CYP4A11LOXL2ALDH1A1HPGD
SCHEMBL5724917 0.75 CYP4F2 (0.63) CYP4F2CYP4A11LOXL2TRPV1ALDH1A1
SCHEMBL8993207 0.75 PTGER4 (0.55) CYP4F2CYP4A11HSP90AA1LOXL2PTGER4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023186881-A1 P38 MAP KINASE INHIBITORS FOR USE IN THE TREATMENT OF COLORECTAL CANCER BADEN-WÜRTTEMBERG STIFTUNG GGMBH (DE) 2023-10-05 WO disclosed
US-20230017312-A1 CENTRALLY ACTIVE P38ALPHA INHIBITING COMPOUNDS SYNOVO GMBH (DE) 2023-01-19 US disclosed
US-20230017312-A1 CENTRALLY ACTIVE P38ALPHA INHIBITING COMPOUNDS SYNOVO GMBH (DE) 2023-01-19 US disclosed
WO-2021038292-A1 CENTRALLY ACTIVE P38ALPHA INHIBITING COMPOUNDS SYNOVO GMBH (DE) 2021-03-04 WO disclosed
WO-2021038292-A1 CENTRALLY ACTIVE P38ALPHA INHIBITING COMPOUNDS SYNOVO GMBH (DE) 2021-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230017312-A1 CENTRALLY ACTIVE P38ALPHA INHIBITING COMPOUNDS MAPK1, MAPK8, MAPK7 CYP4F2 2652/4885CYP4A11 602/4885ACHE 2686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.